Skip to main content
Institutional profile

Cellectis

Cellectis is one of the earlier pioneers in gene-edited allogeneic cell therapy. The company focuses on using gene editing to create off-the-shelf CAR-T cell therapies, primarily for oncology.

  • Highest 2026 tier: Tier III
  • Cell & Gene Therapy Developers
  • 1 ranking category

Overview

Cellectis is one of the earlier pioneers in gene-edited allogeneic cell therapy. The company focuses on using gene editing to create off-the-shelf CAR-T cell therapies, primarily for oncology.

Cellectis’ strength lies in its technical orientation. Allogeneic cell therapy could improve scalability and availability compared with autologous CAR-T, but it also faces challenges around persistence, rejection, safety, and clinical efficacy.

Cellectis is included in 1 2026 ranking category. Its highest classification is Tier III. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.

Firm facts

Public identityCellectis
Founded1999
Institution typeCell & Gene Therapy Developers institution
HeadquartersParis, France / New York, United States
Primary focusCell & Gene Therapy Developers
Highest 2026 ranking tierTier III

Principal activities

Cellectis’ strength lies in its technical orientation. Allogeneic cell therapy could improve scalability and availability compared with autologous CAR-T, but it also faces challenges around persistence, rejection, safety, and clinical efficacy.

Core capability

Cell & Gene Therapy Developers

Client relevance

Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.

Execution and verification

Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.

Sector and mandate coverage

Primary category

Cell & Gene Therapy Developers

Institutional context

Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.

Market position

The company’s long history, gene-edited cell therapy platform, and continuing clinical development relevance support its inclusion among specialist developers.

Cellectis is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier III.

Competitive context

The relevant peer set varies by category, geography, client segment and mandate. Cellectis should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.

Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.

Leadership and governance

Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.

Corporate and public information

The public-facing organization is identified here as Cellectis. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.

Corporate and disclosure information
OrganizationCellectis
HeadquartersParis, France / New York, United States
Verification noteConfirm legal entity, licenses, offices and engagement terms directly before appointment or use.

Additional published ranking appearances

These entries retain the edition, classification and assessed business name published in the source. Historical entries describe that edition, including businesses whose ownership or name later changed.

Published rankingEdition / tierAssessed business
Top 20 Cell & Gene Therapy Developers 20252025 · Tier IIICellectis
Top 20 Cell & Gene Therapy Developers 20242024 · Tier IIICellectis
Top 20 Cell & Gene Therapy Developers 20232023 · Tier IIICellectis

Rankings and recognition

2026

Tier III

Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.

Related Economy analysis

Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:

Sources and data transparency

Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.

  1. Healthcare Ranking — Top 30 Cell & Gene Therapy Developers 2026 — 2026 inclusion and tier classification.
  2. The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
  3. The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
  4. The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.

Corrections and Updates

Factual corrections, updated institutional information, and supporting references may be submitted through The Economy Portal. All proposed changes are subject to editorial verification before publication.

First published: 29 August 2026

Last substantively reviewed: 29 August 2026

Profile scope: Cell & Gene Therapy Developers

This profile has been compiled from publicly available institutional and editorial sources. The profiled organization does not determine its inclusion, editorial characterization or ranking status.

Documented company information

Company inception 1999 is distinct from legal incorporation as French société anonyme on January 4, 2000. Source.

Current company mission body explicitly identifies Paris headquarters. The 2025 annual filing separately gives principal executive offices at 8 rue de la Croix Jarry, 75013 Paris. Source 1; Source 2.